2-hydroxy-5-bromobenzoyl-(6`-pergamon-3`-al)-hydrazone having coagulation activity

 

(57) Abstract:

Usage: in medicine to create drugs that have coagulation activity. The inventive product 2-hydroxy-5-bromobenzoyl-( 6 Pergamon - 3-al) hydrazone. C17H10BrFN2O4. So pl. 257-258C. At a dose of 10 mg/kg reduces the clotting time of up to 100 6,5, M m LD50is 1,800 mg/kg of Reagent 1: 6-Pergamon-3-aldehyde. The hydrazide reagent 2 5-bromosalicylic acid. Process conditions: heated on a water bath for 3 hours, the Yield was 73% 1 table.

The invention relates to chemical-pharmaceutical industry, namely to new biological active substances, based on which you can create new drugs that have coagulation activity.

The claimed connection relates to new derivatives of chromone, namely replaced the hydrazones chroman-3-aldehyde of the formula

< / BR>
Here is the application of a derived chromone, its properties and biological activity not described in literature.

The closest similar in structure and action to the claimed connection is menadione [1]

< / BR>
The aim of the invention is to obtain a new derivative chromone with bermula

which is obtained by condensation of 6-Pergamon-3-aldehyde and hydrazide 5-bromosalicylic acid.

P R I m m e R. 2-Hydroxy-5-bromobenzoyl-(6l-Pergamon-3l-al) hydrazone. To a solution of 1.9 g of 6-Pergamon-3-aldehyde (0.01 mol) in 15 ml dry toluene was added 2,31 g of the hydrazide 5-bromosalicylic acid. The reaction mixture is heated on a water bath for 3 h, after which the solvent is distilled under vacuum. After recrystallization from isopropyl alcohol to obtain 2.35 g of a yellow crystalline powder. Yield 73% of theoretical. So pl. 257-258aboutC.

Calculated With 50,38; N 2,47; N 6,92.

WITH17H10BrFN2O4< / BR>
Found, With 51,04; N 2,69; N Is 6.78.

The IR-spectrum, liquid paraffin, 1650, 1570, 1150 (cm-1)

Study of the biological activity was carried out in the laboratory of pharmacological screening at the Department of organic chemistry EPM. The effect of compounds on blood coagulation was carried out on awake white rats-males weighing 200-230 g Blood for the study was taken from the Vienna language and recorded coagulation tests using standard coagulogram N-338-1. Record on paper tape counted the blood clotting time. At the same time held the role) and standard vikasola at a dose of 10 mg/kg A new connection at a dose of 10 mg/kg, and saline solution and the standard was introduced in two steps: 24 and 1 h before the start of the experiment. The reference drug (menadione) is proposed as a comparator drug in the study of coagulation activity.

The results of the experiments are statistically processed [3] and is shown in the table.

Determination of acute toxicity and calculations LD50carried out according to the method of Cerberus [2] White mice weighing 18-20 g were injected intraperitoneally 0.5 ml of the suspension of the analyte prepared by adding 1-2 drops of Tween-80. At each dose in the experience took 6 mice. Found that LD50the analyte is more than 1800 mg/kg, therefore, this compound belongs to the class of practically non-toxic compounds.

The results of these studies show that the claimed compound has a pronounced hemostatic effect greater than the effect of a drug vikasola, being practically non-toxic. This indicates the feasibility of further studies of this material with the aim of creating effective drug.

2-Hydroxy-5-bromobenzoyl-( 6-Pergamon - 3-al)-

 

Same patents:

The invention relates to chemical-pharmaceutical industry, namely to new biologically active substances on the basis of which can be created drugs that have anti-allergic activity

The invention relates to chemical-pharmaceutical industry, namely to new biologically active substances on the basis of which can be created drugs that have anti-allergic activity

The invention relates to methods of optical separation pornoencaricaturas compounds, which are important intermediate product in the synthesis of optically active derivative of pianolasociety, useful in the treatment of hypertension (hypertension) and asthma

The invention relates to medicine, in particular to neurosurgery

The invention relates to medicine, namely to methods for treatment of viral respiratory diseases and can be used in clinical practice

The invention relates to a method for producing novel compounds that have biological activity similar to the activity retinova acid, more specifically, to methods and intermediate products used in the synthesis dogsleding acetylene compounds with similar retinova acid activity

The invention relates to veterinary medicine, in particular to methods for prevention of acute respiratory diseases in calves and can be used for prophylaxis of respiratory diseases, mainly acute respiratory infections of bacterial etiology
The invention relates to medicine, particularly cardiology, and is intended for treatment of cardiac arrhythmias

The invention relates to methods for producing compounds of formula I HOOCwhere Y is-CO-, or-CH2-;

Y is a bond or-O-;

p = 1-16; and

Z is-H or-G-Q, where G is a simple bond or-CH= CH-;

and Q is phenyl, substituted C1-C3the alkoxy group

The invention relates to new derivatives of 4-promenaden, namely derivatives of the formula

where I R1= -OH

R2= --CH3R3= - OH

II R1= -H; R2= -C1; R3= -OH

III R1= -O--CH3; R2= -H;

R3= -Nhaving antiallergic activity, which can be used in medicine

The invention relates to medicine and can be used in pediatric patients for the treatment of complex grits I degree

FIELD: organic synthesis.

SUBSTANCE: invention provides compounds of general formula I:

, where R1 represents -CO-Ra, -SO2-Rb, or aryl optionally substituted by lower alkoxy, wherein Ra represents cycloalkyl, cycloalkyl(lower)alkyl, cycloalkyloxy, aryl, aryloxy, aryl(lower)alkyl, aryl(lower)alkoxy, aryloxy(lower)alkyl, aryl-S-(lower)alkyl, aryl(lower)alkenyl, provided that aryl group can be optionally substituted by halogen, lower alkyl, hydroxy, nitro, cyano, lower alkoxy, phenyl, CF3, cyano(lower)alkyl, lower alkyl-C(O)NH, lower alkyl-CO, and lower alkyl-S; heteroaryl, heteroaryl(lower)alkyl, or heteroaryl(lower)alkoxy, provided that heteroaryl group is 5- or 6-membered ring or bicyclic aromatic group constituted by two 5- or 6-membered rings including 1-3 heteroatoms selected from oxygen, nitrogen, and sulfur and that heteroaryl group can be optionally substituted by lower alkoxy; Rb represents aryl, aryl(lower)alkyl, or heteroaryl, aryl group optionally substituted by halogen, cyano, or lower alkyl-C(O)NH; R2 and R3 represent hydrogen atoms; R4 representshydrogen or lower alkyl; R5 represents hydrogen, lower alkyl, cycloalkyl, benzodioxyl, or aryl optionally substituted by lower alkyl, halogen, lower alkoxy, hydroxy, or (lower)alkyl-C(O)O; n is 1 or 2; and pharmaceutically acceptable salts thereof and/or pharmaceutically acceptable esters thereof. Invention also provides a pharmaceutical composition exhibiting inhibitory activity with regard to cysteine proteases of the cathepsin family, which composition comprises compound of formula I, pharmaceutically acceptable recipient, and/or adjuvant.

EFFECT: increased choice of cysteine protease inhibitors.

34 cl, 1 tbl, 13 ex

FIELD: organic chemistry, chemical technology, medicine, biochemistry, pharmacy.

SUBSTANCE: invention relates to new derivatives of sulfonamides of the formula (I) or their pharmaceutically acceptable salts wherein R1 means -OH or -NHOH; R2 means hydrogen atom; R3 means alkyl, alkoxyalkyl, arylalkyl, pyridylalkyl or morpholinylalkyl; A means piperidyl or tetrahydrofuranyl; n = 0; E means a covalent bond; (C1-C4)-alkylene, -C(=O)-, -C(=O)O- or -SO2-; X means hydrogen atom, alkyl, aryl, arylalkyl, alkoxyalkyl, morpholinyl or tetrahydropyranyl; each among G and G' means -C(R5)=C(R5') wherein R5 and R5' mean hydrogen atom; M means the group -CH-; z means the group -(CR7R7')a-L-R8 wherein a = 0 and each among R7 and R7' means hydrogen atom; L means a covalent bond; R8 means halogen atom or alkoxy-group. Compounds of the formula (I) are inhibitors of metalloproteases and can be used for treatment of arthritis, cancer tumors and other diseases.

EFFECT: valuable medicinal properties of compounds.

15 cl, 7 tbl, 56 ex

FIELD: medicine.

SUBSTANCE: before applying substitute hormonal therapy (SHT) on should evaluate antithrombogenic activity of vascular wall in women. For this purpose one should determine quantitative values of ADP-induced aggregation of thrombocytes, activity of antithrombin III in blood and fibrinolytic blood activity both before and after "cuff"-test. Then one should detect the indices calculated as the ratio of mentioned values both before and after carrying out the mentioned test. If mentioned indices are decreased against the norm by 20-40% women should be prescribed to undergo SHT at additional introduction of aspirin and supradin. The method provides prophylaxis of cardio-vascular diseases in this category of female patients due to correcting affected functional activity of vascular endothelium.

EFFECT: higher efficiency of prophylaxis.

1 cl, 1 ex, 4 tbl

FIELD: medicine, natural compounds.

SUBSTANCE: larch wood is saturated with water and extraction with ethyl acetate is carried out. Prepared extract is treated with hot water and this process is combined with distilling off a solvent. Then water-insoluble resin impurities are separated and crude product is isolated by crystallization and recrystallized. Invention provides simplifying the process.

EFFECT: improved preparing method.

2 ex

FIELD: medicine, pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to compositions used for treatment and/or prophylaxis of chlamydium infections caused by C. pheumoniae. Pharmaceutical composition used for treatment and/or prophylaxis of chlamydium infection caused by C. pneumoniae comprises the taken phenolic compound, or extract, or fraction, or incomplete fraction comprising the taken phenolic compound or corresponding synthetic compound, or mixture of indicated compounds obtained from plants. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction obtained from plants and comprising indicated compound or corresponding synthetic compound on C. pneumoniae represents the definite percent of inhibition for formation of inclusions. The composition useful for health eliciting an anti-chlamydium effect with respect to C. pneumoniae comprises the taken phenolic compound or extract, or fraction, or incomplete fraction containing indicated compound or corresponding synthetic compound, or mixture of indicated compounds obtained from plants. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound obtained from plants on C. pneumoniae represents the definite percent for inhibition in formation of inclusions. Also, invention relates to applying the composition useful for health in preparing foodstuffs or as supplements for nutrition for every day. Also, invention relates to applying phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound or mixture of indicated compounds obtained from plants in manufacturing a medicinal agent used for treatment and/or prophylaxis of chlamydium infections caused by C. pneumoniae. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound obtained from plants on C. pneumoniae represents the definite percent in inhibition in formation of inclusions. Compositions promote to effective prophylaxis and treatment of chlamydium infections caused by C. pneumoniae.

EFFECT: valuable medicinal properties of compounds.

21 cl, 1 dwg, 1 tbl, 6 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to new compounds of coumarone class, namely, to 6-nitro-2-iminocoumarin 3-carboxylic acid 4-toluidide silver salt of the formula (1): that elicits an antibacterial effect and can be used in medicine. Invention provides preparing a new compound eliciting an antibacterial effect with respect to S. aureus, E. coli, and C. albicans with mononuclear cells values 0.25; 0.5 and 7.8 mcg/ml, respectively, and with acute toxicity value LD50 for these compounds 2 460 230 mg/kg.

EFFECT: valuable properties of compound.

1 cl, 1 tbl, 2 ex

FIELD: organic chemistry, medicine, pharmacology.

SUBSTANCE: invention relates to new derivatives of carbamic acid esters of the general formula (I):

and their pharmaceutically acceptable salts eliciting activity with respect to metabotropic glutamate receptors mGlu of group I that can be used for treatment of acute and/or chronic neurological disorders. In the general formula (I) R1 means hydrogen atom or (C1-C7)-alkyl; R2 and R2' mean independently of one another hydrogen atom, (C1-C7)-alkyl, (C1-C7)-alkoxy-group, halogen atom or trifluoromethyl; X means oxygen (O), sulfur (S) atom or two hydrogen atoms not forming a bridge; A1/A2 mean independently of one another phenyl or 6-membered heterocycle comprising 1 or 2 nitrogen atom; B represents group of the formula:

wherein R3 means (C1-C7)-alkyl and others; Y means -O-, -S- or a bond; Z means -O- or -S-; or B means 5-membered heterocyclic group of formulae: (a) , (b) , (c) or (d) . Also, invention relates to methods for preparing compounds and to a medicinal agent based on thereof.

EFFECT: improved preparing methods, valuable medicinal properties of compounds.

22 cl, 1 tbl, 2 sch, 78 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with phospholipid complexes of proanthocyanidine A2 and pharmaceutical compositions upon their basis as antiatherosclerotic agents, those for preventing and treating myocardial and cerebral infarction. Phospholipids of the above-mentioned complex should be preferably chosen out of lecithins, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine. The innovation provides the preparation to treat the above-mentioned diseases due to decreasing the quantity and burden of atheromatous plaque, decreased obstruction of carotid arteries and decreased thickness of vascular walls.

EFFECT: higher efficiency of prophylaxis and therapy.

9 cl, 11 dwg, 6 ex, 2 tbl

FIELD: pharmaceutical chemistry.

SUBSTANCE: invention relates to treatment of patients suffering from diseases associated with pathologic activity of matrix proteases. Treatment involves administration of compounds depicted by general formula (I).

EFFECT: increased treatment efficiency.

136 cl, 448 ex

Up!